Integrating Patient-Centric Clinical Pharmacology and MID3 to Advance Biologic Development in Immune-Mediated Inflammatory Diseases.
Advances in biologics and model-informed drug discovery and development (MID3) are transforming the treatment of immune-mediated inflammatory diseases (IMIDs). By integrating pharmacokinetics and pharmacodynamics, MID3 enables mechanism-based, patient-centered strategies to optimize therapies, strengthen benefit-risk a...